Discover how molecular biomarkers such as HER2, KRAS, and PD-L1 are helping guide treatment selection, clinical trials, and personalized cancer care.
Learn how polygenic risk scores are reshaping cancer prevention by combining thousands of genetic variants to improve risk prediction, personalize screening, and guide earlier preventive care.
Discover how precision medicine is transforming immunotherapy through biomarkers like PD-L1, TMB, and MSI-helping clinicians identify the right patients for the right cancer treatments.
Learn how targeted therapies match drugs to cancer-driving mutations, advancing precision oncology and improving treatment outcomes.
Liquid biopsy is transforming cancer detection through minimally invasive genomic testing, offering new opportunities for earlier diagnosis and monitoring.
Shraddha HakaniPrecision medicine in oncology is no longer a distant vision- it is a critical necessity. As cancer care evolves, biomarker-driven diagnostics, genomic sequencing, digital pathology, and AI-powered insights are transforming how clinicians detect.
A multidisciplinary community committed to advancing research, education, and clinical standards in precision medicine.
Copyright 2026. American Board of Precision Medicine. All Rights Reserved.
